This clinical trial looks at a new treatment called bulumtatug fuvedotin. It is for patients with triple-negative breast cancer who have already received other treatments. The main goal is to see if this new treatment can be effective for these patients.
The trial's ID number is NCT06908928. This is a Phase 1 trial, which means it is looking at how well the treatment works and its safety. It is FDA-regulated and aims to include around 52 participants.
Who can join
This trial is open to adults aged 18 and older, both men and women. Participants must have specific types of breast cancer and have received certain prior treatments. Those with unstable health conditions or certain infections cannot join. The trial team will confirm who is eligible before joining.
Condition
Triple Negative Breast Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be divided into two groups by chance. One group will receive a lower dose of bulumtatug fuvedotin, and the other group will receive a higher dose. The treatment is given through an intravenous infusion on specific days during a 21-day cycle. Everyone will receive the treatment.
Where
This trial is enrolling at 6 locations. Recruiting sites are listed first.
Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery, WashU. Treats breast cancer. Works as a surgical oncologist. Based in St. Louis, Missouri. Chosen on merit.
Microsurgical breast reconstruction specialist, MSK. Treats breast cancer and mouth cancer. Offers microsurgical breast reconstruction, head and neck reconstruction and abdominal wall reconstruction. Works as a plastic & reconstructive surgeon. Based in New York. Chosen on merit.